Media Outlets Discuss COVID-19 Research, Scientific Developments, Including Launch Of Human Trials For Novel Coronavirus Vaccine Candidates

The Hill: Human testing beginning on second coronavirus vaccine candidate (Klar, 4/7).

PRI: Research on COVID-19 vaccine shows unique global collaboration, says Ebola vaccine scientist (Woolf, 4/7).

Reuters: Novavax to start human trial for novel coronavirus vaccine (Hussain/Joseph, 4/8).

Science Magazine: Former FDA leaders decry emergency authorization of malaria drugs for coronavirus (Piller, 4/7).

Science Magazine: Trials of drugs to prevent coronavirus infection begin in health care workers (Kupferschmidt, 4/7).

STAT: New research examines wastewater to detect community spread of Covid-19 (Chakradhar, 4/7).

UPI: Trials begin for potential COVID-19 drug remdesivir (Norton, 4/6).

Wall Street Journal: Hunt Is on for Genetic Clues to Why Coronavirus Impact Varies (Marcus, 4/7).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.